REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink or control th…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC